Patient-related outcomes five years after coronary artery bypass graft surgery. by Skinner, J, Farrer, M, Albers, C, Neil, H, Adams, P

High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coronary artery bypass graft surgery. by Skinner, J, Farrer, M, Albers, C, Neil, H, Adams, P

Clinical outcome measures eight years following Coronary Artery Bypass Grafting (CABG): A prospective cohort study by Mackin, P, Skinner, J, Farrer, M, Albers, C, Neil, H, Adams, P

Assessing the impact of blood sample type on the estimated prevalence of impaired glucose tolerance and diabetes mellitus in epidemiological surveys. by Farrer, M, Albers, C, Neil, H, Adams, P, Laker, M, Alberti, K

Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. by Skinner, J, Farrer, M, Albers, C, Piper, K, Neil, H, Adams, P

Patients undergoing coronary artery bypass graft surgery are at high risk of impaired glucose tolerance and diabetes mellitus during the first postoperative year. by Farrer, M, Fulcher, G, Albers, C, Neil, H, Adams, P, Alberti, K

A comparative study of Lrrk2 function in primary neuronal cultures. by Dächsel, J, Behrouz, B, Yue, M, Beevers, J, Melrose, H, Farrer, M

Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. by Farrer, M, Winocour, P, Evans, K, Neil, H, Laker, M, Kesteven, P, Alberti, K

Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. by Farrer, M, Game, F, Albers, C, Neil, H, Winocour, P, Laker, M, Adams, P, Alberti, K

Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease. by Farrer, M, Game, F, Albers, C, Neil, H, Winocour, P, Laker, M, Adams, P, Alberti, K

Relation between insulinemia, body mass index, and lipoprotein composition in healthy, nondiabetic men and women. by Winocour, P, Kaluvya, S, Ramaiya, K, Brown, L, Millar, J, Farrer, M, Neil, H, Laker, M, Alberti, K

α-synuclein genetic variability: A biomarker for dementia in Parkinson disease by Guella, I, Evans, D, Szu-Tu, C, Nosova, E, Bortnick, S, Goldman, J, Dalrymple-Alford, J, Geurtsen, G, Litvan, I, Ross, O, Middleton, L, Parkkinen, L, Farrer, M

LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. by Hinkle, K, Yue, M, Behrouz, B, Dächsel, J, Lincoln, S, Bowles, E, Beevers, J, Dugger, B, Winner, B, Prots, I, Kent, C, Nishioka, K, Lin, W, Dickson, D, Janus, C, Farrer, M, Melrose, H

DNAJC12 and dopa-responsive nonprogressive parkinsonism by Straniero, L, Guella, I, Cilia, R, Parkkinen, L, Rimoldi, V, Young, A, Asselta, R, Soldà, G, Sossi, V, Stoessl, A, Priori, A, Nishioka, K, Hattori, N, Follett, J, Rajput, A, Blau, N, Pezzoli, G, Farrer, M, Goldwurm, S, Rajput, A, Duga, S

DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study by Parkkinen, L, Trinh, J, Gustavsson, E, Vilariño-Güell, C, Bortnick, S, Latourelle, J, McKenzie, M, Tu, C, Nosova, E, Khinda, J, Milnerwood, A, Lesage, S, Brice, A, Tazir, M, Aasly, J, Haytural, H, Foroud, T, Myers, R, Ben Sassi, S, Hentati, E, Nabli, F, Farhat, E, Amouri, R, Hentati, F, Farrer, M